Bufalin Enhances Immune Responses in Leukemic Mice Through Enhancing Phagocytosis of MacrophageIn Vivo
| Autor: | Yung Liang Chen, Chao Ping Chen, Yung Luen Shih, Hsueh Yu Chung, Shu Ching Hsueh, Kuo Wei Chen, Mei Hui Lee, Hsin Tu Hou, Ming Zhe Lee, Jiann Shang Chou, Jing Gung Chung, Hsu Feng Lu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cytotoxicity
Immunologic Male 0301 basic medicine Cancer Research T-Lymphocytes Phagocytosis Spleen Pharmacology Lymphocyte Activation Peripheral blood mononuclear cell General Biochemistry Genetics and Molecular Biology Mice 03 medical and health sciences 0302 clinical medicine Immune system In vivo Cell Line Tumor medicine Animals Cytotoxic T cell B-Lymphocytes Mice Inbred BALB C Leukemia Chemistry Macrophages Bufalin medicine.disease Bufanolides Killer Cells Natural 030104 developmental biology medicine.anatomical_structure Liver 030220 oncology & carcinogenesis Biomarkers Research Article |
| Zdroj: | In Vivo. 32:1129-1136 |
| ISSN: | 1791-7549 0258-851X |
| DOI: | 10.21873/invivo.11355 |
| Popis: | Background/aim Bufalin, bufadienolide present in Chan Su, has been shown to induce cancer cell apoptosis in many human cancer cells, including human leukemia cells, but its effects on immune responses are unknown. Materials and methods This study investigated whether bufalin affected immune responses of mice with WEHI-3 cell-generated leukemia in vivo. BALB/c mice were intraperitoneally injected with WEHI-3 cells to develop leukemia and then were treated with oral treatment with bufalin at different doses (0, 0.1, 0.2 and 0.4 mg/kg) for 2 weeks. At the end of treatment, all mice were weighted and blood was collected; liver and spleen tissues were collected for cell marker, phagocytosis, natural killer (NK) cell activity and T- and B-cell proliferation measurements by using flow cytometric assays. Results When compared with the leukemia control group, bufalin increased the body weight, but reduced liver and spleen weights, and reduced CD3, CD16 and Mac-3 cell markers at 0.4 mg/kg treatment and increased CD11b marker at 0.1 and 0.2 mg/kg treatment. Furthermore, bufalin at 0.4 mg/kg increased phagocytosis by macrophages isolated from peripheral blood mononuclear cells and at 0.1 mg/kg by those from the peritoneal cavity. Bufalin (0.2 and 0.4 mg/kg) increased NK cell cytotoxic activity at effector:target ratio of 50:1. Bufalin increased B-cell proliferation at 0.1 and 0.2 mg/kg treatment but only increased T-cell proliferation at 0.1 mg/kg. Bufalin increased glutamate oxaloacetate transaminase level at all dose treatments, increased glutamic pyruvic transaminase level only at 0.1 mg/kg treatment, but reduced the level of lactate dehydrogenase at all dose levels in mice with WEHI-3 cell-induced leukemia in vivo. Conclusion Bufalin increased immune responses by enhancing phagocytosis in mice with leukemia mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|